Q-omics provides the consensus-scored IER5 profile across patient tissues and cancer cell-line models. IER5 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, IER5 is differentially expressed in 14, with the highest sampling consensus in THCA. Additionally, IER5 RNA expression shows 18,123 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRP, THCA, and UVM as cancer lineages where IER5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IER5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IER5 survival associations across molecular data types. IER5 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IER5 RNA expression–survival associations across cancer types. High IER5 expression shows unfavorable associations in KIRP, LGG, LIHC, LUSC and READ, but favorable associations in UCEC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for IER5 RNA expression.
This table summarizes IER5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for IER5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IER5 shows lower tumor expression in BRCA and higher tumor expression in THCA, KIRC, HNSC, LIHC and COAD. The THCA box plot shows higher IER5 RNA expression in tumor versus normal tissue (log2 FC = +1.095, t-test p < 0.001).
This table shows molecular features associated with IER5 in patient tissues and cancer cell lines. In patient samples, IER5 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, IER5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in BONE and SKIN.
